Last reviewed · How we verify

Skin disinfection

Poitiers University Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Skin disinfection is a Small molecule drug developed by Poitiers University Hospital. It is currently FDA-approved.

Skin disinfection is a process that involves applying a disinfectant to reduce levels of microorganisms on the skin, which is an important part of surgery for both patient and healthcare provider skin. Chlorhexidine gluconate is a disinfectant used in skin disinfection, as seen in clinical trials such as NCT01782573, which studied its efficacy in preventing surgical site infections for patients undergoing hepatectomy.

At a glance

Generic nameSkin disinfection
SponsorPoitiers University Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Skin disinfection

What is Skin disinfection?

Skin disinfection is a Small molecule drug developed by Poitiers University Hospital.

Who makes Skin disinfection?

Skin disinfection is developed and marketed by Poitiers University Hospital (see full Poitiers University Hospital pipeline at /company/poitiers-university-hospital).

What development phase is Skin disinfection in?

Skin disinfection is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing